[MET扩增介导的晚期非小细胞肺癌获得性耐药的研究进展]
[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].
作者信息
Pan Sisi, Wang Na, Song Xia
机构信息
The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China.
The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2022 Aug 20;25(8):615-621. doi: 10.3779/j.issn.1009-3419.2022.102.23.
Abstract
Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in oncogene-driven NSCLC and summarize the progress of clinical strategies to overcome the resistance mechanism. .
摘要
间充质-上皮转化因子（MET）扩增是表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）耐药的重要驱动因素，MET原癌基因（MET）与EGFR酪氨酸激酶抑制剂（TKIs）联合使用在克服这种分子定义的获得性耐药方面已显示出前景。新出现的数据还表明，MET扩增是TKIs治疗的间变性淋巴瘤激酶（ALK）、RET和ROS1融合NSCLC的耐药驱动因素。在此，我们综述了关于MET扩增作为致癌基因驱动的NSCLC靶向治疗耐药驱动因素的最新研究进展文献，并总结了克服耐药机制的临床策略进展。
相似文献
1
[Research Progress of Acquired Resistance Mediated by MET Amplification
in Advanced Non-small Cell Lung Cancer].[MET扩增介导的晚期非小细胞肺癌获得性耐药的研究进展]
Zhongguo Fei Ai Za Zhi. 2022 Aug 20;25(8):615-621. doi: 10.3779/j.issn.1009-3419.2022.102.23.
2
[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].[MET基因变异型非小细胞肺癌治疗的研究进展：综述]
Zhongguo Fei Ai Za Zhi. 2022 Dec 20;25(12):877-887. doi: 10.3779/j.issn.1009-3419.2022.101.54.
3
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.超越表皮生长因子受体：MET 扩增作为驱动基因非小细胞肺癌中靶向治疗的一般耐药驱动因素。
ESMO Open. 2021 Dec;6(6):100319. doi: 10.1016/j.esmoop.2021.100319. Epub 2021 Nov 24.
4
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
5
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。
J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.
6
Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.生物标志物指导治疗在老年驱动基因阳性晚期非小细胞肺癌中的应用：老年肿瘤国际协作组青年委员会报告。
J Geriatr Oncol. 2022 Nov;13(8):1071-1083. doi: 10.1016/j.jgo.2022.04.013. Epub 2022 May 5.
7
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.克隆性 MET 扩增作为表皮生长因子受体突变型非小细胞肺癌酪氨酸激酶抑制剂耐药的决定因素。
J Clin Oncol. 2019 Apr 10;37(11):876-884. doi: 10.1200/JCO.18.00177. Epub 2019 Jan 24.
8
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.一名对克唑替尼产生获得性耐药的ALK（间变性淋巴瘤激酶）阳性肺腺癌患者同时发生EGFR（表皮生长因子受体）和KRAS（V-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物）突变：病例报告
BMC Res Notes. 2013 Nov 26;6:489. doi: 10.1186/1756-0500-6-489.
9
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.非小细胞肺癌中表皮生长因子受体通路依赖性获得性表皮生长因子受体酪氨酸激酶抑制剂耐药。
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
10
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.在非小细胞肺癌和卵巢癌模型的临床前研究中发现一种新型的 ALK/ROS1/FAK 抑制剂 APG-2449。
BMC Cancer. 2022 Jul 11;22(1):752. doi: 10.1186/s12885-022-09799-4.
本文引用的文献
1
Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.转染重排阳性患者对塞尔帕替尼联合克唑替尼治疗无反应，且获得性塞尔帕替尼耐药：病例报告。
Anticancer Drugs. 2022 Aug 1;33(7):682-685. doi: 10.1097/CAD.0000000000001291. Epub 2022 Mar 23.
2
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.RET 驱动的肺和甲状腺癌中 RET 抑制剂耐药的演变。
Nat Commun. 2022 Mar 18;13(1):1450. doi: 10.1038/s41467-022-28848-x.
3
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.一项关于表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKI）耐药后，EGFR突变型非小细胞肺癌中EGFR和MET联合抑制有效性的大型真实世界研究。
Front Oncol. 2021 Oct 1;11:722039. doi: 10.3389/fonc.2021.722039. eCollection 2021.
4
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer.MET 外显子 14 跳跃突变型肺癌对致癌开关和单药 MET 抑制剂的敏感性。
Sci Transl Med. 2021 Sep;13(609):eabb3738. doi: 10.1126/scitranslmed.abb3738. Epub 2021 Sep 1.
5
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).奥沙利铂治疗后进展的 EGFR 敏感突变阳性的晚期/转移性非小细胞肺癌患者的生物标志物指导的 II 期平台研究（ORCHARD）。
Clin Lung Cancer. 2021 Nov;22(6):601-606. doi: 10.1016/j.cllc.2021.06.006. Epub 2021 Jun 25.
6
KRAS Inhibitor Resistance in -Amplified Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.KRAS 抑制剂耐药性在 -扩增非小细胞肺癌中由 RAS 和非 RAS 介导的细胞信号转导机制诱导。
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7.
7
Acquired Resistance to KRAS Inhibition in Cancer.癌症中对 KRAS 抑制的获得性耐药。
N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281.
8
Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
9
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.ALK 重排的非小细胞肺癌中 MET 扩增导致的早期阿来替尼耐药：对克唑替尼的反应及对阿来替尼和克唑替尼的再次反应
Clin Lung Cancer. 2021 Nov;22(6):e851-e855. doi: 10.1016/j.cllc.2021.04.008. Epub 2021 Apr 27.
10
Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer.病例报告：高水平MET扩增作为ROS1重排非小细胞肺癌中ROS1酪氨酸激酶抑制剂的耐药机制
Front Oncol. 2021 May 13;11:645224. doi: 10.3389/fonc.2021.645224. eCollection 2021.
Zotero 插件